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Gangliosides, the sialic acid-conjugated glycosphingolipids present in the lipid rafts, have been recognized as important regulators
of cell proliferation, migration, and apoptosis. Due to their peculiar localization in the cell membrane, they modulate the activity of
several key cell receptors, and increasing evidence supports their involvement also in stem cell diﬀerentiation. In this context, herein
we report the role played by the ganglioside GM1 in the osteogenic diﬀerentiation of human tendon stem cells (hTSCs). In
particular, we found an increase of GM1 levels during osteogenesis that is instrumental for driving the process. In fact,
supplementation of the ganglioside in the medium signiﬁcantly increased the osteogenic diﬀerentiation capability of hTSCs.
Mechanistically, we found that GM1 supplementation caused a reduction in the phosphorylation of the platelet-derived growth
factor receptor-β (PDGFR-β), which is a known inhibitor of osteogenic commitment. These results were further corroborated
by the observation that GM1 supplementation was able to revert the inhibitory eﬀects on osteogenesis when the process was
inhibited with exogenous PDGF.
1. Introduction
Injuries to the tendon-to-bone enthesis are common in the
ﬁeld of orthopedic medicine, and high failure rates are often
associated with their repair [1]. The use of biologic adjuvants
that promote tissue regeneration, such as growth factors,
platelet-rich plasma, and stem cells, have shown great poten-
tial for improving healing rates and function after surgery
[2]. Accordingly, the use of tendon stem cells to improve
tendon-bone junction repair has been considered advanta-
geous, as tendon stem cells already belong to the tendon envi-
ronment and possess the plasticity to potentially recover the
diﬀerent tissues found in the tendon-to-bone enthesis [3].
Along these lines, we reported the ﬁrst isolation of human
tendon stem cells from the supraspinatus and long head of
the biceps tendons, and we demonstrated that they can be
induced to diﬀerentiate toward osteoblasts, adipocytes, and
muscle cells [4]. Nonetheless, an open issue in the stem cell
ﬁeld is to perfect the diﬀerentiation strategies in order to
drive the process toward a speciﬁc phenotype and to avoid
undesired cell commitment or, even more detrimental, the
uncontrolled proliferation of undiﬀerentiated progenitor
cells. In this context, herein we investigated the role of gangli-
osides, which are sialic acid-containing glycosphingolipids
(GSLs) ubiquitously distributed in cell membranes [5], in
the osteogenic diﬀerentiation of hTSCs. Numerous studies
have conﬁrmed that gangliosides and their expression levels
are controlled during development [6] and are cell type-
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speciﬁc [7], supporting the idea that these molecules are key
players in cell commitment. While some biological roles of
these lipids have been clearly recognized, as they have been
shown to be involved in processes like cell proliferation [8],
cell adhesion [9], apoptosis [10], and diﬀerentiation [11], less
is known about their role in stem cell homeostasis and diﬀer-
entiation. Nonetheless, it has been shown that a reduction of
ganglioside biosynthesis inhibits the neuronal diﬀerentiation
of MSCs in the early stage of the process [12], and our group
recently demonstrated that an increase of ganglioside GD1a
is crucial for human bone marrow mesenchymal stem cell
(MSC) diﬀerentiation [13]. Moreover, we demonstrated the
pivotal role of sialidase NEU3 in regulating ganglioside
GM3 content, which is a key in skeletal muscle cell diﬀeren-
tiation and survival under hypoxia [14–17]. Clearly, as gan-
gliosides are mainly distributed in the lipid rafts of cell
plasma membranes, which are rich in key tyrosine kinase
receptors, the present study further corroborates the notion
that we are at the beginning of fully unveiling the role of these
sphingolipids in stem cell biology.
2. Materials and Methods
2.1. Cell Isolation and Culture. Human tendon stem cells
(hTSCs) were isolated from supraspinatus tendon speci-
mens collected during arthroscopic rotator cuﬀ repair, as
previously reported [4]. The isolated hTSCs were cultured
in minimal essential medium alpha modiﬁcation (α-MEM)
(Merck) supplemented with 2mM L-glutamine (Euroclone),
1% antibiotic-antimycotic mixture (Euroclone), and 20%
(v/v) fetal bovine serum (FBS) (HyClone, Thermo Fisher
Scientiﬁc) at 37°C in a 5% CO2 and 95% air-humidiﬁed
atmosphere. The medium was changed every 2-3 days.
2.2. Osteogenic and Adipogenic Diﬀerentiation. hTSCs were
seeded at a concentration of 3× 104 cells/cm2 in a growth
medium, and after 24 hours, cells were switched to an
osteogenic or adipogenic medium for 17 days or 21 days,
respectively. Osteogenic diﬀerentiation was obtained by
culturing cells in the presence of DMEM-low glucose
(Merck) supplemented with 4mM L-glutamine (Euroclone),
1% antibiotic-antimycotic mixture (Euroclone), 10% FBS
(HyClone, Thermo Fisher Scientiﬁc), 10 nM cholecalciferol
(Merck Millipore), and the mesenchymal stem cell osteogen-
esis kit (Merck Millipore) according to the manufacturer’s
instructions. Adipogenic diﬀerentiation was induced by cul-
turing cells in the presence of DMEM-low glucose supple-
mented with 4mM L-glutamine, 1% antibiotic-antimycotic
mixture, 10% FBS, and the mesenchymal stem cell adipogen-
esis kit (Merck Millipore), according to the manufacturer’s
instructions. To evaluate the eﬀects of ganglioside GM1
treatment (Santa Cruz Biotechnology) on diﬀerentiation,
hTSCs were cultured for 17 days in an osteogenic medium
or 21 days in adipogenic medium supplemented with 1,
10, 50, and 100μM GM1. To evaluate the eﬀects of the
platelet-derived growth factor-BB (PDGF-BB, Thermo
Fisher Scientiﬁc) on osteogenic diﬀerentiation, cells were
cultured in an osteogenic medium containing PDGF-BB
at the ﬁnal concentration of 10 ng/ml. The diﬀerentiation
medium was changed every 2-3 days.
2.3. Metabolic Radiolabeling of Cell Sphingolipids. The meta-
bolic radiolabeling of cell sphingolipids was performed as
previously described by Riboni et al. [18]. Brieﬂy, [3-3H]-
sphingosine (D-erythro> 97%, 50μCi, 1.85MBq, PerkinEl-
mer) was dissolved in DMEM-low glucose with 10% FBS to
a ﬁnal concentration of 2.4 nM sphingosine, corresponding
to 110.000 dpm/ml radioactivity. The medium was added to
the cells and incubated for 2 hours (pulse) at 37°C, then it
was replaced with DMEM-low glucose with 10% FBS without
[3H]-sphingosine for 48 hours (chase). After the incubation,
cells were harvested by cell scraping in phosphate-buﬀered
saline (PBS). Cell suspensions were frozen and lyophilized.
2.4. Extraction and Chromatographic Separation of
Radiolabeled Sphingolipids. Total lipid extraction was per-
formed as previously described by Bergante et al. [13].
Brieﬂy, lipids were ﬁrst extracted with 20 : 10 : 1 (v/v) chloro-
form/methanol/water, dried under a nitrogen stream, and
then a two-phase partitioning was carried out in chloro-
form/methanol 2 : 1 (v/v) and 20% (v/v) water. After partition-
ing, gangliosides of the aqueous phase were separated and
analyzed by high-performance thin-layer chromatography
(HPTLC), using as running solvent chloroform/methanol/
0.2% aqueous CaCl2 60 : 40 : 9 (v/v/v) [19, 20]. Radiolabeled
sphingolipids were visualized with a Beta-Imager 2000 (Bio-
space). The radioactivity associated with individual lipids
was determined with β-Vision software (Biospace).
2.5. RNA Extraction and Real-Time PCR. Total RNA was
isolated using TRIzol Reagent (Ambion, Life Technologies),
and 1μg of extracted RNA was reverse transcribed to cDNA
using the iScript cDNA synthesis kit (Bio-Rad) according to
the manufacturer’s instructions. Real-time PCR was per-
formed in a 96-well plate with 10 ng of cDNA as a template,
0.2μM primers, and 2x Power SYBR Green PCR Master Mix
(Promega) in 20μL ﬁnal volume per well, using a StepOne-
Plus Real-Time PCR System (Applied Biosystems). The fol-
lowing primers were used to amplify the corresponding
target genes: human alkaline phosphatase (ALP) forward
5′-CGCACGGAACTCCTGACC-3′ and reverse 5′-GCCA
CCACCACCATCTCG-3′, peroxisome proliferator-activated
receptor-γ (PPAR-γ) forward 5′-TTCCTTCACTGATACA
CTGTCTGC-3′ and reverse 5′-GGAGTGGGAGTGGTCT
TCCATTAC-3′, lipoprotein lipase (LPL) forward 5′-AG
AGAGAACCAGACTCCAATG-3′ and reverse 5′-GGCT
CCAAGGCTGTATCC-3′, beta 1,3-galactosyltransferase
(GM1 synthase) forward 5′-CGCCTTCCAGGACTCCTA
CC-3′ and reverse 5′-CCGTCTTGAGGACGTATCGG-3′,
osteocalcin forward 5′-GCAGCGAGGTAGTGAAGAG-3′
and reverse 5′-GAAAGCCGATGTGGTCAGC-3′, and S14
(used as endogenous control in all real-time PCR experi-
ments) forward 5′-GTGTGACTGGTGGGATGAAGG-3′
and reverse 5′-TTGATGTGTAGGGCGGTGATAC-3′.
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2.6. Analysis of Mineralization. Matrix mineralization of
hTSCs was evaluated at the 17th day of osteogenic diﬀerenti-
ation using the osteogenesis assay kit (Merck Millipore).
Brieﬂy, cells were ﬁxed with 4% paraformaldehyde at room
temperature for 15 minutes. In order to detect mineral depo-
sition in the extracellular matrix, cells were washed twice
with PBS and incubated with alizarin red stain solution for
20 minutes. The dye was then extracted from the stained
monolayer according to the manufacturer’s instructions
and quantiﬁed using a Victor 3 instrument (Perkin Elmer).
2.7. Immunoblotting. Cells were harvested in ice-cold PBS by
cell scraping and centrifuged at 400×g for 10 minutes at 4°C.
Cells were lysed in RIPA buﬀer (150mM sodium chloride,
1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulphate, and 50mMTris pH8) containing complete
protease and phosphatase inhibitors (Merck). After cell lysis,
the samples were centrifuged at 10,000×g for 15 minutes at
4°C. Protein amounts were measured using a Pierce BCA
protein assay kit (Thermo Scientiﬁc). Proteins were loaded
into a 10% SDS-PAGE gel, then transferred onto a nitrocellu-
lose membrane (Trans-Blot, Bio-Rad Laboratories) by elec-
troblotting. After blocking the membranes with 5% (w/v) of
nonfat dry milk in Tris-buﬀered saline-Tween 0.1% (TBS-
T) for 1 hour at room temperature, they were incubated over-
night at 4°C with the following primary antibodies: rabbit
phospho-PDGFR-β, 1 : 1000 dilution (Y751, Cell Signaling);
rabbit PDGFR-β, 1 : 1000 dilution (Cell Signaling); and rabbit
monoclonal early endosome antigen 1 (EEA1), 1 : 1000 dilu-
tion (Cell Signaling). The membranes were then washed in
TBS-T three times and incubated for 1 hour at room temper-
ature with speciﬁc secondary antibodies. In particular, phos-
pho-PDGFR-β was incubated with the IRDye® 800CW goat
anti-mouse IgG (LI-COR), the total PDGFR-β with the
IRDye 680RD goat anti-rabbit IgG (Li-COR), and EEA1 with
the HRP-conjugated anti-rabbit IgG (Amersham), diluted
1 : 5000 in 5% (w/v) nonfat dry milk in TBS-T. The mem-
branes were analyzed by the Odyssey® FC imaging system
(LI-COR), and the densitometric analysis was performed
with the speciﬁc Image Studio™ software (LI-COR).
3. Results
3.1. Ganglioside Changes in hTSC Diﬀerentiation toward
Osteoblasts and Adipocytes. To assess the ganglioside pattern
distribution of hTSCs, cells were metabolically radiolabeled
with the sphingolipid precursor [3-3H]-sphingosine and
quantitatively analyzed by HTPLC coupled with a radio-
chromatoscanner, as described in “Materials and Methods.”
The ganglioside distribution in proliferating hTSCs was as
follows: GM3 (30.79%± 7.85), GM2 (2.53%± 2.33), GM1
(7.28%± 2.94), GD3 (43.83%± 19.35), and GD1a (4.71%±
2.80), with GM3 and GD3 being the main gangliosides
(Figure 1(a) and 1(b), T0).
Next, changes in ganglioside pattern were evaluated upon
diﬀerentiation of hTSCs to either osteoblasts or adipocytes,
as previously reported [4], by metabolic radiolabeling after
17 and 21 days of cell culturing in either osteogenic (O.D.)
or adipogenic (A.D.) medium (Figure 1(a)). When hTSCs
were diﬀerentiated toward osteoblasts, a 1.6- and 2.8-fold
increase of GM3 and GM1 gangliosides was observed,
respectively, as well as a 3.7-fold decrease of GD3, as com-
pared to proliferating undiﬀerentiated cells. When hTSCs
were diﬀerentiated toward adipocytes, a 1.7-fold increase in
GM3 and 1.5-fold decrease in GD3 relative distribution were
observed, as compared to undiﬀerentiated cells, while no sig-
niﬁcant changes in the relative quantity of GM1 could be
observed (Figure 1(a)). To test whether the observed increase
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Figure 1: Ganglioside pattern upon diﬀerentiation of hTSCs to either osteoblasts or adipocytes. (a) Metabolic radiolabeled gangliosides
separated by HPTLC and visualized with a Beta-Imager 2000 (Biospace). Doubled spots in cellular gangliosides correspond to the
presence of species with diﬀerent chain lengths of fatty acids. The graph on the right represents the percentage distribution of radiolabeled
gangliosides. (b) Real-time PCR analysis of GM1 synthase gene expression in hTSCs diﬀerentiated toward osteoblasts (O.D.) or adipocytes
(A.D.) as compared to that in undiﬀerentiated cells (T0). Ribosomal protein S14 gene was used as housekeeper gene. All data are
means± SD of three diﬀerent experiments. The statistical analysis was determined by Student’s t-test. ∗p < 0 05, ∗∗∗p < 0 001.
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of GM1 during osteogenesis was due to an upregulation of its
biosynthesis, GM1 synthase expression was measured by
real-time PCR, and a 2.6-fold increase could be observed at
the end of the diﬀerentiation process, as compared to prolif-
erating hTSCs. On the other hand, a 3.2-fold reduction of
GM1 synthase expression was measured when hTSCs were
induced to diﬀerentiate toward adipocytes (Figure 1(b)).
3.2. Eﬀects of Exogenous GM1 on Osteogenic Diﬀerentiation of
hTSCs. To test the role of GM1 increase during osteogenesis,
exogenous 1, 10, 50, and 100μM GM1 was supplemented in
the osteogenic medium during the diﬀerentiation process.
Osteogenic marker ALP gene expression was measured by
real-time PCR after 17 days of diﬀerentiation and compared
to undiﬀerentiated cells (T0) and GM1-free osteogenic
medium (O.D.). Results showed a signiﬁcant 1.8- and 2.4-
fold increase in ALP expression when cells were supple-
mented with 50 or 100μMGM1 in addition to the osteogenic
medium, respectively, as compared to O.D. (Figure 2(a)).
Afterward, cells were induced to diﬀerentiate to osteo-
blasts in the presence of 50 or 100μM GM1 and were
evaluated for their capacity to sustain the mineralization
of the extracellular matrix using a standard alizarin red
staining, as described in “Materials and Methods.” Dye rela-
tive quantiﬁcation showed an increase of red staining in
hTSCs diﬀerentiated in the presence of GM1, which was sig-
niﬁcantly higher (1.7-fold) in 100μM GM1-treated cells
(Figure 2(b)). On the contrary, exogenous GM1 strongly
inhibited the gene expression of the adipogenic markers
LPL and PPAR-γ (Figures 2(c) and 2(d)).
3.3. Mechanism of GM1-Activated Osteogenesis. To test
whether osteogenesis was activated by GM1 through the
inhibition of PDGFR-β, hTSCs were induced to diﬀerentiate
in the presence of the ganglioside and then subjected to
PDGFR-β analysis by Western blot. Results revealed that
GM1-treated cells showed a 40% decrease in PDGFR-β phos-
phorylation, measured as the pPDGFR/PDGFR ratio, as
compared to untreated cells, supporting the hypothesis of a
GM1-induced inhibition of PDGFR-β (Figure 3(a)). Further-
more, it was assessed whether exogenous GM1 was able to
counteract PDGF-induced activation of PDGFR-β, which is
known to inhibit osteogenesis [21]. To this purpose, hTSCs
were induced to diﬀerentiate for 17 days in normal osteo-
genic medium in the presence of 10 ng/ml PDGF-BB, which
caused a 43% decrease in ALP expression (Figure 3(b)) and
a 40% decrease in osteocalcin expression by real-time PCR
(Figure 3(c)). On the other hand, addition of 100μM GM1
to the osteogenic medium containing 10ng/ml PDGF-BB
completely restored the diﬀerentiation capability of hTSCs,
as ALP and osteocalcin expression levels were comparable
to diﬀerentiated untreated controls (Figure 3(b) and 3(c)).
4. Discussion
In this work, we investigated the role of gangliosides in the
osteogenic diﬀerentiation of adult human tendon stem cells
that we isolated and characterized for the ﬁrst time from
human supraspinatus tendons [4]. The method used for
ganglioside pattern analysis required an initial metabolic
radiolabeling of cell sphingolipids by adding [3-3H]-sphingo-
sine in the culture medium that has been eﬀectively used in
our laboratories for many years [13–15]. As a result, cells
synthesize radiolabeled sphingolipids that can be separated
by HPTLC chromatography and accurately measured with
a radiochromatoscanner. The use of metabolic radiolabeling
signiﬁcantly improves the sensitivity of the method, reducing
the number of stem cells required for each analysis. Results
demonstrated that the two main gangliosides of hTSCs,
GM3 and GD3, increased and decreased, respectively, when
cells were diﬀerentiated toward osteoblasts or adipocytes,
suggesting that the modulation of these gangliosides is possi-
bly linked to a general change of the biological status of the
cell and not to the commitment toward a speciﬁc cell lineage.
On the other hand, a marked increase of ganglioside GM1
was observed only during osteogenesis, supporting the possi-
ble role of this ganglioside in driving the process (Figure 1).
The increase in GM1 content was accompanied by an
increase of its synthase, which was instead reduced during
adipogenesis (Figure 1). Interestingly, the addition of exoge-
nous GM1 to the diﬀerentiation medium improved osteo-
genesis, as conﬁrmed by a signiﬁcant increase of ALP gene
expression, which is a speciﬁc osteoblast marker, as well as
by an increase of the extracellular matrix mineralization, as
assessed by alizarin red staining (Figure 2). On the contrary,
gene expression of the adipogenic markers PPAR-γ and LPL
decreased upon GM1 supplementation to the adipogenic dif-
ferentiation medium, supporting the idea that the ganglioside
could inhibit the process (Figure 2). We then investigated the
mechanism of GM1-induced increase of osteogenesis in
hTSCs. Along this line, it has been reported that gangliosides
can regulate the activity of the epidermal growth factor
receptor [22], the ﬁbroblast growth factor receptor [23], the
nerve growth factor receptor (NGF) [24], the platelet-
derived growth factor receptor (PDGFR) [25], and the insu-
lin receptor (IR) [26]. In particular, it has been shown that
GM1 is crucial in PDGFR regulation through diﬀerent mech-
anisms of action that appear to be cell type-dependent. In this
context, it has been demonstrated that, in ﬁbroblasts, GM1 is
able to inhibit the ligand-mediated phosphorylation of tyro-
sine residues of the cytoplasmic tail of the receptor [27], as
well as the ligand-induced intracellular association of SH2-
containing proteins with PDGFR in human glioma cells
[28]. On the contrary, in Swiss-3T3 cells, it has been demon-
strated that GM1-mediated inhibition of PDGFR requires
the extracellular and/or the transmembrane domains of the
receptor [29]. Moreover, in the same cell line, it has been
shown that GM1 regulates PDGFR signaling by controlling
the distribution of the receptor in- and outside of lipid
rafts and that PAG regulates the membrane partitioning
and the mitogenic signaling of PDGFR through an increase
in GM1 levels in caveolae [30, 31]. PDGF/PDGFR signaling
is reported to be involved in the regulation of various cell
functions, including osteogenesis and adult stem cell dif-
ferentiation toward osteoblasts. In particular, it has been
observed that the downregulation of PDGRα promotes oste-
ogenic diﬀerentiation of MSCs through the BMP/smad sig-
naling pathway [32], and the blocking of the PDGFR-β
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pathway markedly promotes osteoblast diﬀerentiation and
matrix mineralization in mouse osteoblastic MC3T3-E1 cells
[33]. Moreover, PDGFR-β inhibition increases the osteo-
genic diﬀerentiation of primary rat osteoblastic cells [34]
and human MSCs [21]. Altogether, these results support
the hypothesis that GM1 could exert its eﬀects on osteogen-
esis through the inhibition of the PDGF receptor also in
hTSCs. To test this hypothesis, we assessed the activation
levels of the PDGFR-β receptor during osteogenesis in the
presence of exogenous GM1 in the culture medium. Indeed,
we observed a signiﬁcant decrease in the activation of the
receptor when GM1 was added to the diﬀerentiation medium
(Figure 3). To further conﬁrm our hypothesis, we assessed
whether GM1 was able to counteract the inhibition of osteo-
genesis caused by the activation of PDGFR-β upon addition
of its ligand (PDGF-BB) in the diﬀerentiation medium.
Results showed that PDGF-BB stimulation inhibited osteo-
genesis, as conﬁrmed by a signiﬁcant decrease of ALP and
osteocalcin gene expression. As anticipated, the addition of
GM1 to the osteogenic medium containing PDGF-BB
completely restored the diﬀerentiation capabilities of hTSCs,
as we could observe ALP and osteocalcin expression levels
similar to untreated control cells (Figure 3).
5. Conclusions
In conclusion, our results show that ganglioside GM1 signif-
icantly increases during osteogenic diﬀerentiation of hTSCs.
Most importantly, the ganglioside increase is instrumental
for driving the process through the inhibition of PDGFR-β.
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Figure 2: Evaluation of hTSC diﬀerentiation either to osteoblasts and adipocytes upon GM1 treatment. (a) Gene expression of the osteogenic
marker ALP by real-time PCR. hTSCs were diﬀerentiated toward osteoblasts for 17 days in osteogenic medium supplemented with exogenous
1, 10, 50, and 100μM GM1. The results were compared to hTSCs diﬀerentiated in GM1-free osteogenic medium (O.D.). Ribosomal protein
S14 gene was used as endogenous control. (b) Analysis and quantiﬁcation of calcium deposits in hTSCs after osteogenic diﬀerentiation by
alizarin red staining. Undiﬀerentiated hTSCs and hTSCs diﬀerentiated in the presence of 50μM and 100μM GM1 were compared to
hTSCs diﬀerentiated in GM1-free osteogenic medium (O.D.) and considered as controls. (c, d) Gene expression analysis of adipogenic
markers, PPAR-γ and LPL, by real-time PCR. hTSCs were diﬀerentiated toward adipocytes for 21 days in adipogenic medium
supplemented with exogenous 1, 10, 50, and 100 μM GM1. The results were compared to hTSCs diﬀerentiated in GM1-free adipogenic
medium (A.D.). Ribosomal protein S14 gene was used as endogenous control. All data are means± SD of four diﬀerent experiments. The
statistical analysis was determined by Student’s t-test. ∗p < 0 05, ∗∗p < 0 01.
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Indeed, the addition of exogenous GM1 to the diﬀerentia-
tion medium greatly increased the osteogenic capabilities
of hTSCs, supporting its possible use as a new factor to be
added in the diﬀerentiation medium to improve this pro-
cess. Further studies are ongoing in our laboratories to fully
elucidate the mechanism of GM1 regulation of PDGFR-β
activation and the possible therapeutic application of GM1
in regenerative medicine.
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Figure 3: Eﬀects of GM1 treatment on PDGFR activation. (a) Western blot analysis and quantiﬁcation of PDGFR-β activation. hTSCs were
diﬀerentiated toward osteoblasts in osteogenic medium supplemented with 100 μM GM1, as compared to hTSCs diﬀerentiated in GM1-free
osteogenic medium (O.D.). Total proteins were extracted and analyzed with anti-phosphorylated-PDGFR-β (Tyr 751) antibody (green) and
anti-PDGFR-β (28E1) antibody (red). EEA1 expression was used as internal control. Data are means± SD of four diﬀerent experiments. (b, c)
Gene expression analysis of the osteogenic markers ALP and osteocalcin by real-time PCR. hTSCs were diﬀerentiated toward osteoblasts in
osteogenic medium supplemented with 100μMGM1 or 10 ng/ml PDGF-BB or with both 100 μMGM1 and 10 ng/ml PDGF-BB. The results
were compared to hTSCs diﬀerentiated in free osteogenic medium (O.D.). Ribosomal protein S14 gene was used as housekeeper. All data are
means± SD of three diﬀerent experiments. The statistical analysis was determined by Student’s t-test. ∗p < 0 05, ∗∗p < 0 01, ∗∗∗p < 0 001.
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